Ferinject

ApprovedSmall molecule

VVifor Pharma

Ferinject is one of 325 small molecule programs targeting Blood Transfusion. It is currently in Approved.

Indications

Total Trials

Active Trials

324

Competitors

Pipeline

Status by Indication[3][1]

Indication

Blood TransfusionActive, not recruiting

Endothelial DysfunctionActive, not recruiting

Hip FractureActive, not recruiting

Myocardial InfarctionActive, not recruiting

Iron Deficiency AnemiaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

AnemiaActive, not recruiting

Coronary Artery BypassActive, not recruiting

Inflammatory Bowel DiseaseActive, not recruiting

Gastric CancerActive, not recruiting

Blood TransfusionApproved

Active, not recruiting

Endothelial DysfunctionApproved

Active, not recruiting

Hip FractureApproved

Active, not recruiting

Myocardial InfarctionApproved

Active, not recruiting

Iron Deficiency AnemiaApproved

Active, not recruiting

Metastatic Colorectal CancerPhase 2

Active, not recruiting

AnemiaPhase 3

Active, not recruiting

Coronary Artery BypassApproved

Active, not recruiting

Inflammatory Bowel DiseasePhase 2

Active, not recruiting

Gastric CancerPhase 3

Active, not recruiting

Showing 10 of 13 indications

Competition

Competitive Landscape

714 competitors in Gastric Cancer

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

18 2

Ferinject

VVifor Pharma

Approved

1 3

Gemzar

Johnson & Johnson

Preclinical

—4

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

3 5

S1,

CChinese Academy of Medical Sciences

Preclinical

17 6

PD-1 Inhibitor

Johnson & Johnson

Preclinical

3 7

Induction Phase1

Genmab

Preclinical

1 8

Glutamine

Sanofi

Preclinical

1 9

Human Albumin

TTonghua Anrate Biopharmaceutical Co., Ltd.

Preclinical

1 10

Cox-2 Inhibitor

SSeoul National University Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

ApprovedRecruiting

Chronic Heart Failure

NCT05793996

Post-ApprovalRecruiting

Myocardial Infarction

NCT05759078

Q1 2027

Post-ApprovalNot yet recruiting

Musculoskeletal

NCT05708170

Clinical

Trials by Indication[1]

Anemia5 trials

Impact and Evaluation of the Management of Iron Deficiency With or Without Anemia in Patients With Cancer

Completed·IInstitut Cancerologie de l'Ouest·N/A·NCT03625661·257 enrolled

Intravenous Iron Injection in Cancer Patients With Anemia

Unknown status·SSamsung Medical Center·Phase 3·NCT04187716·341 enrolled

Ferinject® Assessment In GastRectomy Patients With Acute Isovolemic Anemia (FAIRY)

Completed·NNational Cancer Center, Korea·Phase 3·NCT01725789·454 enrolled

Show 2 more trials

The Efficacy of Intravenous Iron for the Treatment of Anemia in Cancer Patients

Unknown status·SSamsung Medical Center·Phase 2·NCT02599012·100 enrolled

The Use of Iron Therapy for Patients With Anemia After Caesarean Section

Terminated·MMaastricht University Medical Center·Phase 4·NCT01975272·27 enrolled

Heart Failure4 trials

Ferinject® Assessment in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF)

Completed·VVifor Pharma·Phase 3·NCT00520780·456 enrolled

EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart Failure

Terminated·VVifor Pharma·Phase 3·NCT00821717·35 enrolled

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure

Completed·VVifor Pharma·Phase 3·NCT01394562·174 enrolled

Show 1 more trial

A Study to Compare the Use of Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency

Completed·VVifor Pharma·Phase 4·NCT01453608·304 enrolled

Blood Transfusion1 trial

The Effect of Ferric Carboxymaltose on Hemoglobin and Blood Transfusion in Cardiac Surgery

Unknown status·RRambam Health Care Campus·Phase 4·NCT02939794·200 enrolled

Metastatic Colorectal Cancer1 trial

Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution in Patients With Metastatic Colorectal Cancer (CRC) and Iron Deficiency Anemia: a Randomized Multicenter Treatment Optimization Study.

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT02469480·64 enrolled

Iron deficiency anemia1 trial

Comparison Between Outcomes of Pregnant Women Treated With Ferinject vs. Venofer for Iron Deficiency Anemia

Unknown status·WWestern Galilee Hospital-Nahariya·Phase 4·NCT06061393·200 enrolled

17 more indications

Coronary Artery Bypass1 trial

Effect of Intravenous Ferric Carboxymaltose on Hemoglobin Response and Transfusion in Patients With Iron Deficiency Anemia After Off-Pump Coronary Artery Bypass Grafting

Unknown status·YYonsei University·Phase 4·NCT04898569·100 enrolled

Myocardial Infarction1 trial

Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion

Recruiting·WWroclaw Medical University·Phase 4·NCT05759078·1,000 enrolled

CLE1 trial

The Iron and Muscle Study

Completed·KKing's College Hospital NHS Trust·Phase 4·NCT04862715·75 enrolled

Efficacy and Safety1 trial

Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women

Completed·VVifor Pharma·Phase 3·NCT01131624·252 enrolled

Endothelial Dysfunction1 trial

Acute Effects of Intravenous Iron on Oxidative Stress and Endothelial Dysfunction in Non-dialysis CKD

Unknown status·—·Phase 4·NCT03388385·40 enrolled

Maintenance Treatment1 trial

Maintenance Treatment of Iron Deficiency in IBD Patients

Completed·VVifor Pharma·Phase 3·NCT00810004·245 enrolled

Fatigue1 trial

Ferric Carboxymaltose Treatment to Improve Fatigue Symptoms in Iron-deficient Non-anaemic Women of Child Bearing Age

Completed·VVifor Pharma·Phase 4·NCT01110356·294 enrolled

Hip Fracture1 trial

Intravenous Iron Supplement to Prevent Postoperative Delirium After Hip Fracture Surgery

Unknown status·SSeoul National University Bundang Hospital·Phase 4·NCT05429749·264 enrolled

Gastric Cancer1 trial

Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC)

Unknown status·—·Phase 3·NCT05226169·330 enrolled

Musculoskeletal1 trial

Impact of Intravenous Iron on Musculoskeletal Function in Older Adults

Not yet recruiting·LLiverpool Hope University·Phase 4·NCT05708170·100 enrolled

Erythropoietin1 trial

Intravenous Ferric Carboxymaltose (Ferinject®) With or Without Erythropoietin in Patients Undergoing Orthopaedic Surgery

Terminated·UUniversity of Zurich·Phase 4·NCT00706667·75 enrolled

GastroIntestinal Bleeding1 trial

Efficacy of Parenteral Iron Supplementation After Gastrointestinal Bleeding in Subjects Over 65

Completed·UUniversity Hospital, Rouen·Phase 3·NCT01690585·62 enrolled

Inflammatory Bowel Disease1 trial

Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD)

Terminated·VVifor Pharma·Phase 2·NCT00882414·26 enrolled

Efficacy1 trial

Efficacy of Ferric Carboxymaltose (Ferinject®) in Anemic Patients Anticipating Pancreatoduodenectomy

Completed·NNational Cancer Center, Korea·Phase 2·NCT02628860·40 enrolled

Celiac Disease1 trial

Effect of Intravenous Iron Supplementation on Celiac Disease Remission in Patients With Iron Deficiency and Intestinal Villous Atrophy: a Randomized Trial

Terminated·AAssistance Publique - Hôpitaux de Paris·Approved·NCT05114278·1 enrolled

Chronic Heart Failure1 trial

Study of the Prevalence of Iron Deficiency Among Hospitalized Patients With HFpEF and the Impact of Ferinject® on Indicators of Quality of Life, Functional Status in Patients With Iron Deficiency

Recruiting·TTomsk National Research Medical Center of the Russian Academy of Sciences·Approved·NCT05793996·100 enrolled

Unspecified1 trial

Iron Long-Term Labelling Study Switzerland

Unknown status·PProf. Michael B. Zimmermann·N/A·NCT02979132·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 29 trial records for Ferinject. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ferinject compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ferinject. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vifor Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: VVifor Pharma

Ferinject

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Anemia5 trials

Heart Failure4 trials

Blood Transfusion1 trial

Metastatic Colorectal Cancer1 trial

Iron deficiency anemia1 trial

Coronary Artery Bypass1 trial

Myocardial Infarction1 trial

CLE1 trial

Efficacy and Safety1 trial

Endothelial Dysfunction1 trial

Maintenance Treatment1 trial

Fatigue1 trial

Hip Fracture1 trial

Gastric Cancer1 trial

Musculoskeletal1 trial

Erythropoietin1 trial

GastroIntestinal Bleeding1 trial

Inflammatory Bowel Disease1 trial

Efficacy1 trial

Celiac Disease1 trial

Chronic Heart Failure1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News